|Day Low/High||6.47 / 6.95|
|52 Wk Low/High||5.70 / 10.51|
Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017
Totaling $29.5 Million in payments from HTIT received to date
Totaling $25.5 M in payments from HTIT received to date
Payment comes in wake of positive topline phase IIB results
All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT
Patent addresses platform technology for oral insulin capsule ORMD-0801
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share
180 Patients Expected to be Enrolled in Study
These under-$10 stocks are within range of triggering breakout trades.